Sign in
MEIP Stock Price, Chart, Stats & News
MEI Pharma, Inc.
Save
20.45M
Market cap
–
Current P/E
–
Forward P/E
MEIP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 35.87% |
Operating margin | -3282.44% |
Pretax margin | -3319.31% |
Net margin | -3319.31% |
Effective tax rate | – |
ROA | -47.87% |
ROE | -68.86% |
D/E | – |
Interest coverage ratio | – |
MEIP valuation
P/E | – |
P/S | 17.10x |
P/B | 1.40x |
P/CF | -9.43x |
P/FCF | -1.68x |
P/OCF | -9.43x |
PEG | 0.09x |
EV multiple | -0.75x |
About
MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm study targeting B-cell malignancies. Additionally, Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, is undergoing Phase Ib clinical trials for acute myeloid leukemia and other B-cell malignancies.
Similar securities
Based on sector and market capitalization
Report issue